N/A N=99 Laparoscopic Complete Mesocolic Excision on Colon Cancer
Operation Finding · Complications · Pathology
Primary: Histopathological Outcomes Obtained Through the Surgeries — 20.3; 19.2 nodes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=204 Adjuvant HIPEC in High Risk Colon Cancer
Colorectal Neoplasms · Peritoneal Neoplasms
Primary: Peritoneal Recurrence Free Survival at 18 Months — 79; 80 participants
Phase 2 N=16 Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC)
Colon Cancer · Rectal Cancer
Primary: Efficacy of Lymphoseek for Detection of Sentinel Nodes — 16 Participants
N/A N=269 Complete Histologic Resection of Adenomatous Polyps?
Adenomatous Polyps
Primary: Percent of Incompletely Resected Adenomatous Polyps — 10.1 percentage of incomplete resection
Phase 2 N=64 Neoadjuvant Therapy for Locally Advanced Colon Cancer
Colon Cancer · Neoadjuvant Therapy
Primary: Tumor Regression Rate of MSS/pMMR Patients — 7 Participants
Phase 2 N=21 MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma
Colorectal Neoplasms
Primary: pERK and pAKT Levels in Tumor Biopsies on C1D1 and C1D22 Post-administration of the Combination of AZD6244 Hydrogen Sulfate and MK-2206 in Participants With Advanced…
Phase 2 N=20 Cellular Immune Augmentation in Colon and Rectal Cancer
Colon Cancer · Rectal Cancer
Primary: Participants Exhibiting Immune Response — 11 Participants
N/A N=15 PET-MRI in Diagnosing Patients With Colon or Rectal Cancer
Recurrent Colon Cancer · Recurrent Rectal Cancer · Stage IIA Colon Cancer
Primary: Maximum Standardized Uptake Value (SUVmax) in Physiologic Regions and Fluorodeoxyglucose (FDG) Avid Lesions in Participants Where PET-CT Was Performed Prior to the…
Phase 2 N=33 Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Objective Response Rates (RECIST 1.1) — 42.4 Percentage of participants
Phase 2 N=17 Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery
Colorectal Cancer
Primary: Progression-free Survival (PFS) — 55 Days
Phase 2 N=30 Lymphatic Mapping for Sentinel Node Identification and Analysis
Colorectal Cancer
Primary: Subjects in Which the SLN(s) Are Identified — 27 Participants
N/A N=384 Post-resection Treatment of Large Colon Polyps
Recurrence
Primary: Recurrence — 10; 5; 24 Polyps
N/A N=2,600 The National CT Colonography Trial
Colorectal Cancer
Primary: Number of Participants With Advanced Adenomas (>=10mm) as Determined by Colonoscopy (Per Patient) — 109; 2422 Participants
Phase 2 N=11 TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer
Colorectal Cancer
Primary: Overall Response Rate — 0; 0; 5; 4 Participants
Phase 2 N=100 Effect of Colchicine for the Palliative Management of Hepatocellular Carcinoma
Hepatocellular Carcinoma · Metastasis · Invasion
Primary: Overall Survival — 333; 290 days — p=0.4593
Phase 2 N=72 Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status
Colorectal Neoplasms · Microsatellite Instability
Primary: Overall Response Rate (ORR) — 0 % of participants
N/A N=928 Safety of Endoscopic Resection of Large Colorectal Polyps: A Randomized Trial.
Colon Polyps
Primary: Number of Participants With Delayed Bleeding Complications — 16; 33 Participants
Phase 2 N=4 M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability
Colon Adenocarcinoma · High-Frequency Microsatellite Instability · Metastatic Malignant Solid Neoplasm
Primary: Percentage of Circulating DNA Clearance — 0 percentage of DNA cleared
Phase 2 N=32 Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment
Advanced Colorectal Cancer
Primary: Progression-free Survival Rate at Three Months — 20.7 percentage of participants
Phase 2 N=13 Genistein in Treatment of Metastatic Colorectal Cancer
Colon Cancer · Rectal Cancer · Colorectal Cancer
Primary: Number of Adverse Events — 250; 119; 24; 0 events
Phase 2 N=221 Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab
Colorectal Cancer
Primary: Progression Free Survival — 11.4; 5.9 Months — p=0.004
Phase 2 N=42 Pembrolizumab + Poly-ICLC in MRP Colon Cancer
Metastatic Colon Cancer · Solid Tumor
Primary: Phase 1: Determine the Maximum Tolerated Dose of Poly-ICLC That Can be Combined With Pembrolizumab — 2 mg
Phase 3 N=3,397 Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer
Adenocarcinoma of the Colon · Stage III Colon Cancer
Primary: Disease-free Survival (Arms A and D: Wild-type KRAS Patients) — 74.6; 71.5 percentage of participants
Phase 2 N=40 Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib
Colorectal Adenoma · Colorectal Carcinoma
Primary: Number of Subjects Witha Change (IMPROVEMENT) in Colo-rectal Adenocarcinoma as Measured by Cyclooxygenase-2 Activity After 7 Days of Celecoxib — 2.0; 2.0 Participant
N/A N=265 Colorectal Cancer: Screening vs. Non-Screening
Colorectal Cancer · Screening
Primary: Colorectal Cancer Stage (pTNM) — 46; 85 Participants
Phase 2 N=70 Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)
Colorectal Cancer
Primary: Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 Assessed by Investigator — 7.1 percentage (%) of participants — p=0.2721
Phase 2 N=90 Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery
Colorectal Cancer
Primary: Major Morbidity Related to the Intact Primary Tumor — 16.3 probability of major morbidity (%)
Phase 2 N=45 Open-Label Phase IIb Efficacy Trial of Cancer Macrobeads Compared to Best Supportive Care in Colorectal Cancer Patients
Colorectal Cancers
Primary: Overall Survival — 9.25 months
Phase 2 N=75 Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer
Colon Cancer · Colorectal Cancer
Primary: Maximum Tolerated Dose (MTD) of Celebrex in Combination With EPO906 — 9 mg/m2
N/A N=11,016 Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Colorectal Neoplasms · Digestive System Diseases · Colonic Diseases
Primary: Sensitivity and Specificity of the Exact CRC Screening Test With Comparison to Colonoscopy, Both With Respect to Cancer. — 92.3; 73.8; 93.3; 73.3 percent